A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Paul E. Goss, James N. Ingle, Kathleen I. Pritchard, Hyman Muss, Julie Gralow, Karen A. Gelmon, Timothy Joseph Whelan, Kathrin Strasser-Weippl, Sheldon Rubin, Keren Sturtz, Antonio C. Wolff, Eric P. Winer, Clifford A. Hudis, Alison Stopeck, J. Thaddeus Beck, Judith Salmon Kaur, Kate Whelan, Dongsheng Tu, Wendy R. Parulekar
Institutions: Harvard University, Massachusetts General Hospital, Mayo Clinic, Sunnybrook Health Science Centre, Sunnybrook Hospital, Odette Cancer Centre, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Seattle Cancer Care Alliance, University of Washington, BC Cancer Agency, Cancer Care Ontario, Wilhelminen Hospital, Dalhousie University, Moncton Hospital, Colorado Cancer Research Program, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Highlands Oncology Group, Queen's University, Canadian Cancer Trials Group
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4241517691